1.87
+0.81%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Grace Therapeutics,
From its filings with the US Securities and Exchange Commission
Grace Therapeutics, is based in Princeton, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GRCE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 March 2022, it reported revenue of $100.0m.
We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications.
Our therapeutic pipeline consists of three unique clinical-stage drug candidates supported by an intellectual property portfolio of more than 79 granted and pending patents in various jurisdictions worldwide. These drug candidates aim to improve clinical outcomes in the treatment of rare and orphan diseases by applying proprietary formulation and drug delivery technologies to existing pharmaceutical compounds to achieve improvements over the current standard of care, or to provide treatment for diseases with no currently approved therapies.
Quoted from its 10-K, filed 18 Jun 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Mar 2013
- Employees
- 32
- Website
- acasti.com/en ↗
- Head office
- 103 CARNEGIE CENTER, PRINCETON, NJ, 08540
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Roderick CarterIndependent Chairman of the Board, since 2016
- Mr. Prashant KohliChief Executive Officer
- Mr. Robert DelaversanoPrincipal Financial Officer, Principal Accounting Officer
- Ms. Carrie D'AndreaVice President - Clinical Operations
- Mr. Amresh KumarVice President - Program Management
- Dr. R. Loch MacdonaldChief Medical Officer
- Mr. Michael DerbyIndependent Director
- Mr. Vimal KavuruIndependent Director
- Mr. Donald OldsIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GTX-104 targets subarachnoid hemorrhage, a rare and life-threatening medical emergency.
- GTX-102 addresses ataxia-telangiectasia, a progressive neurodegenerative genetic disease impacting children.
- GTX-101 treats postherpetic neuralgia caused by nerve damage from shingles.
Weaknesses
- The company operates with only thirty-two employees in the pharmaceutical sector.
- Three specific drug candidates are required to address underserved orphan diseases.
- The firm is a late-stage biopharma company with limited workforce size.
Opportunities
- FDA Orphan Drug Designation provides seven years of marketing exclusivity in the US.
- Additional intellectual property protection supports the commercialization of the drug candidates.
- Targeting rare diseases allows for specialized focus within the pharmaceutical industry.
Threats
- Subarachnoid hemorrhage is a rare and life-threatening medical emergency requiring urgent care.
- Ataxia-telangiectasia causes severe disability in children, representing a vulnerable patient population.
- Postherpetic neuralgia is a persistent and often debilitating neuropathic pain condition.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.